# US 2012/0225091 A1 · Modified live (jmso strain) haemophilus parasuis vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0225091 A1
- Document ID: US20120225091A1
- Status: Published application
- Kind: A1
- Application number: 13/385,303
- Filed: 2012-02-13
- Published: 2012-09-06
- Earliest claimed: 2007-03-09
- Assignees: Newport Laboratories, Inc.
- Inventors: Kamesh R. Sirigireddy; Paulraj K. Lawrence; Russell F. Bey; Randy R. Simonson
- Web page: https://patentgrep.com/patent/US20120225091A1

## CPC

- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- C12N 1/205: Bacterial isolates
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12N 9/14: Hydrolases (3)
- C12Y 207/01059: N-Acetylglucosamine kinase (2.7.1.59)
- C12Y 306/03014: H+-transporting two-sector ATPase (3.6.3.14), i.e. F1 ATPase
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/552: {Veterinary vaccine}
- C12R 2001/21: Haemophilus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present invention is a live vaccine from a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth. Several SNPs have been identified as associated with specific proteins that are associated with virulence as seen in the literature in H. parasuis or related bacterial species.

## Claims

### Claim 1

A vaccine for protecting pigs against infection by H. parasuis, comprising a veterinarily acceptable carrier and an immunologically effective amount of live cells of an isolated strain of a serovar derived from a pathogenic parent strain of H. parasuis, wherein said cells exhibit attenuated pathogenicity in pigs as compared to those of the parent strain and wherein said cells are capable of triggering an immune response that protects the pig against H. parasuis infection or reduction in disease when administered as a live vaccine, wherein the parent strain and the isolated strain are serovar 5 of H. parasuis, wherein the vaccine provides heterologous protection against at least serovars 4 and 13.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein the isolated strain was derived from the pathogenic parent strain by MNNG mutagenesis.

### Claim 3 (depends on 2)

The vaccine of claim 2, wherein the isolated strain is dependent on streptomycin for growth, said dependency being associated with a strA gene.

### Claim 4 (depends on 3)

The vaccine of claim 3, wherein the DNA sequence of the strA gene of the parent strain is SEQ ID NO: 1 and wherein the DNA sequence of the strA gene of the isolated strain is SEQ ID NO: 2.

### Claim 5 (depends on 4)

The vaccine of claim 4, wherein the protein encoded by the strA gene of the parent strain is SEQ ID NO: 3 and wherein the protein encoded by the strA gene of the isolated strain is SEQ ID NO: 4.

### Claim 6 (depends on 5)

The vaccine of claim 5, wherein the protein encoded by DNA sequence SEQ ID NO: 1 comprises a portion of 30S ribosomal subunit S12 and the protein encoded by DNA sequence SEQ ID NO: 2 comprises at least one amino acid change in said portion of said 30S ribosomal subunit S12.

### Claim 7 (depends on 4)

The vaccine of claim 4, wherein the strA gene of the isolated strain differs from the strA gene of the parent strain and wherein the difference comprises a change at nucleotide 68 from C to A and a change at nucleotide 272 from C to T.

### Claim 8 (depends on 6)

The vaccine of claim 6, wherein said amino acid change comprises a change at residue 23 from alanine to glutamic acid and a change at residue 91 from proline to leucine.

### Claim 9 (depends on 2)

The vaccine of claim 2, wherein SEQ ID NO: 5 comprises an open reading frame of the parent strain and wherein SEQ ID NO: 6 comprises a protein encoded by SEQ ID NO: 5 and wherein SEQ ID NO: 7 comprises an open reading frame of the isolated strain and wherein SEQ ID NO: 8 comprises a protein encoded by SEQ ID NO:7.

### Claim 10 (depends on 9)

The vaccine of claim 9, wherein the protein encoded by SEQ ID NO: 5 comprises N-acetyl-D-glucosamine kinase and wherein the protein encoded by SEQ ID NO: 7 comprises N-acetyl-D-glucosamine kinase having at least one amino acid change from said protein encoded by SEQ ID NO: 5.

### Claim 11 (depends on 2)

The vaccine of claim 2, wherein SEQ ID NO: 9 comprises an open reading frame of the parent strain and wherein SEQ ID NO: 10 comprises a protein encoded by SEQ ID NO: 9 and wherein SEQ ID NO: 11 comprises an open reading frame of the isolated strain and wherein SEQ ID NO: 12 comprises a protein encoded by SEQ ID NO: 11.

### Claim 12 (depends on 11)

The vaccine of claim 11, wherein the protein encoded by SEQ ID NO: 9 comprises FOF 1 ATP synthase subunit C and wherein the protein encoded by SEQ ID NO: 11 comprises FOF1 ATP synthase subunit C having at least one amino acid change from said protein encoded by SEQ ID NO: 9.

### Claim 13 (depends on 1)

An isolated and purified DNA from the isolated strain of claim 1, said isolated and purified DNA having the nucleotide sequence set forth in SEQ ID NO: 7.

### Claim 14 (depends on 13)

The isolated and purified DNA of claim 13, wherein said isolated and purified DNA codes for a polypeptide having the amino acid sequence set forth in SEQ ID NO: 8.

### Claim 15 (depends on 14)

The isolated DNA of claim 14, wherein said polypeptide comprises N-acetyl-D-glucosamine kinase.

### Claim 16 (depends on 15)

An isolated DNA having at least 85% homology with the DNA of claim 15.

### Claim 17 (depends on 1)

An isolated and purified DNA from the isolated strain of claim 1, said isolated and purified DNA having the nucleotide sequence set forth in SEQ ID NO: 11.

### Claim 18 (depends on 17)

The isolated and purified DNA of claim 17, wherein said isolated and purified DNA codes for a polypeptide having the amino acid sequence set forth in SEQ ID NO: 12.

### Claim 19 (depends on 18)

The isolated and purified DNA of claim 18, wherein said polypeptide comprises FOF1 ATP synthase subunit C.

### Claim 20 (depends on 20)

An isolated DNA having 85% homology with the DNA of claim 20.

### Claim 21 (depends on 1)

An isolated and purified DNA from the isolated strain of claim 1, comprising a combination of SEQ ID NO: 7 and SEQ ID NO: 11.

### Claim 22 (depends on 1)

An isolated and purified DNA from the isolated strain of claim 1, comprising a combination of SEQ ID NO: 2, SEQ ID NO: 7, and SEQ ID NO: 11.
